SWShuyun Wang

Shuyun Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shuyun Wang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Aiqin Gao

    Department of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China

    2 shared publications
  • Fang Zhang

    Central hospital affiliated to Shandong First Medical University 2 Department of Oncology Jinan, 250013 Shandong , P. R. China

    2 shared publications
  • Haiqin Zhang

    Jinan Central Hospital, Shandong University 1 Department of Oncology Jinan, 250013 Shandong , P. R. China

    2 shared publications
  • Wenjing Shi

    Jinan Central Hospital, Shandong University 8 , Jinan, 250013 Shandong , P. R. China

    2 shared publications
  • Xiaozheng Chen

    Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences 7 Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology Jinan, 250117 Shandong , P. R. China

    2 shared publications
  • Yan Zheng

    Research Center of Translational Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, China

    2 shared publications

Latest Publications

  • ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer

    by Haiqin Zhang, Aiqin Gao, Qiaohong Liu, Fang Zhang, Shuyun Wang, Xiaozheng Chen, Wenjing Shi, Ye Zhang, Qian Liu, Yan Zheng, et al.

    Triple-negative breast cancer (TNBC) is the most aggressive and poorly treated subtype of breast cancer. Identifying novel drivers and mechanisms for tumor progression is essential for precise targeted therapy of TNBC. Immunoglobulin-like transcript 4 (ILT4; also known as LILRB2) is a classic myeloid suppressor for their activation and immune response. Our recent results found that ILT4 is also highly expressed in lung cancer cells, where it has a role in promoting immune evasion and thus tumor formation. However, the expression and function of ILT4 in breast cancer remains elusive. Here, using our patient cohort and public database analysis, we found that TNBC displayed the most abundant ILT4 expression among all breast cancer subtypes. Functionally, enriched ILT4 promoted TNBC cell proliferation, migration and invasion in vitro, as well as tumor growth and metastasis in vivo. Further mechanistic analysis revealed that ILT4 reprogrammed aerobic glycolysis of tumor cells via AKT-mTOR signaling-mediated glucose transporter 3 (GLUT3; also known as SLC2A3) and pyruvate kinase muscle 2 (PKM2, an isoform encoded by PKM) overexpression. ILT4 inhibition in TNBC reduced tumor progression and GLUT3 and PKM2 expression in vivo. Our study identified a novel driver for TNBC progression and proposed a promising strategy to combat TNBC by targeting ILT4.


  • Open Access

    Tumor‐derived immunoglobulin like transcript 5 induces suppressive immunocyte infiltration in colorectal cancer

    by Wenjing Shi, Fang Zhang, Xiaozheng Chen, Shuyun Wang, Haiqin Zhang, Zijiang Yang, Guiying Wang, Yan Zheng, Yali Han, Yuping Sun, et al.

    Infiltration of immunosuppressive cells in the tumor microenvironment (TME) induced colorectal cancer (CRC) progression and its resistance to immunotherapy. Identification of tumor‐specific factors to modulate inhibitory immunocyte infiltration would provide alternative and novel targets for CRC immunotherapy. Immunoglobulin‐like transcript (ILT) 5 is a negative regulator of myeloid cell activation. However, its expression and functional role in solid tumors is still unknown. Using human CRC tissues and cell lines, we found that ILT5 was highly expressed in CRC cells compared with normal colorectal epithelial cells. Enriched ILT5 in tumor cells was correlated with advanced tumor stages and poor patient survival. Our subsequent in vitro and in vivo studies revealed that tumor‐derived ILT5 inhibited the infiltration of T cells, especially that of CD8+ T cells in the TME, creating suppressive T‐cell contexture. Furthermore, ILT5 directed M2‐like polarization of tumor‐associated macrophages (TAMs). Inhibition of tumor‐derived ILT5 restored the immunosuppressive T‐cell and TAM contexture, and restricted CRC progression. Our findings identified ILT5 expression in solid tumor cells for the first time and raised ILT5 as a potential immunotarget and prognostic predictor in CRC.